Fibromyalgia is a chronic condition characterized by pain and tenderness. The primary goal of treatment is to reduce the pain, for which multiple well-established treatment options are available, many of which are generic. Even though the majority of the diagnosed fibromyalgia population receives prescription drug treatment, most current therapies suffer from shortcomings in efficacy. The substantial percentage of patients with inadequate pain relief, together with the need for improvement in the treatment of secondary symptoms (e.g., anxiety, major depressive disorder, fatigue) and other areas bearing large unmet need (e.g., drugs that restore neuronal function), poses ample commercial opportunity for a new drug to improve fibromyalgia treatment.


Related Reports

Chronic Pain - Landscape & Forecast - Disease Landscape & Forecast

A crowded generics market makes gaining a strong foothold in the treatment of chronic pain challenging for branded agents. The treatment of chronic pain involves the use of drugs from several drug...

View Details

Rheumatoid Arthritic Pain - Epidemiology - Mature Markets

DRG Epidemiology's coverage of rheumatoid arthritic pain comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France...

View Details

Rheumatoid Arthritic Pain - Epidemiology - Europe

DRG Epidemiology's coverage of rheumatoid arthritic pain comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France...

View Details